144 related articles for article (PubMed ID: 29131061)
1. Kinetic Aspects of Verapamil Binding (On-Rate) on Wild-Type and Six hKv1.3 Mutant Channels.
Diesch AK; Grissmer S
Cell Physiol Biochem; 2017; 44(1):172-184. PubMed ID: 29131061
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the σ-Pore in Mutant hKv1.3 Potassium Channels.
Tyutyaev P; Grissmer S
Cell Physiol Biochem; 2018; 46(3):1112-1121. PubMed ID: 29669325
[TBL] [Abstract][Full Text] [Related]
3. Identification of Verapamil Binding Sites Within Human Kv1.5 Channel Using Mutagenesis and Docking Simulation.
Ding WG; Tano A; Mi X; Kojima A; Seto T; Matsuura H
Cell Physiol Biochem; 2019; 52(2):302-314. PubMed ID: 30816676
[TBL] [Abstract][Full Text] [Related]
4. Effect of K+ and Rb+ on the action of verapamil on a voltage-gated K+ channel, hKv1.3: implications for a second open state?
Kuras Z; Grissmer S
Br J Pharmacol; 2009 Jul; 157(5):757-68. PubMed ID: 19371328
[TBL] [Abstract][Full Text] [Related]
5. Interaction of propofol with voltage-gated human Kv1.5 channel through specific amino acids within the pore region.
Kojima A; Ito Y; Ding WG; Kitagawa H; Matsuura H
Eur J Pharmacol; 2015 Oct; 764():622-632. PubMed ID: 26256861
[TBL] [Abstract][Full Text] [Related]
6. Interactions of Propofol With Human Voltage-gated Kv1.5 Channel Determined by Docking Simulation and Mutagenesis Analyses.
Kojima A; Fukushima Y; Ito Y; Ding WG; Ueda R; Seto T; Kitagawa H; Matsuura H
J Cardiovasc Pharmacol; 2018 Jan; 71(1):10-18. PubMed ID: 29283926
[TBL] [Abstract][Full Text] [Related]
7. Block of the lymphocyte K(+) channel mKv1.3 by the phenylalkylamine verapamil: kinetic aspects of block and disruption of accumulation of block by a single point mutation.
Röbe RJ; Grissmer S
Br J Pharmacol; 2000 Dec; 131(7):1275-84. PubMed ID: 11090098
[TBL] [Abstract][Full Text] [Related]
8. Verapamil- and state-dependent effect of 2-aminoethylmethanethiosulphonate (MTSEA) on hK(v)1.3 channels.
Nikouee A; Janbein M; Grissmer S
Br J Pharmacol; 2012 Nov; 167(6):1378-88. PubMed ID: 22748056
[TBL] [Abstract][Full Text] [Related]
9. Why does the inner-helix mutation A413C double the stoichiometry of Kv1.3 channel block by emopamil but not by verapamil?
Rossokhin A; Dreker T; Grissmer S; Zhorov BS
Mol Pharmacol; 2011 Apr; 79(4):681-91. PubMed ID: 21220411
[TBL] [Abstract][Full Text] [Related]
10. Mapping of maurotoxin binding sites on hKv1.2, hKv1.3, and hIKCa1 channels.
Visan V; Fajloun Z; Sabatier JM; Grissmer S
Mol Pharmacol; 2004 Nov; 66(5):1103-12. PubMed ID: 15286210
[TBL] [Abstract][Full Text] [Related]
11. Acacetin causes a frequency- and use-dependent blockade of hKv1.5 channels by binding to the S6 domain.
Wu HJ; Wu W; Sun HY; Qin GW; Wang HB; Wang P; Yalamanchili HK; Wang J; Tse HF; Lau CP; Vanhoutte PM; Li GR
J Mol Cell Cardiol; 2011 Dec; 51(6):966-73. PubMed ID: 21906601
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis involved in the blocking effect of antidepressant metergoline on C-type inactivation of Kv1.4 channel.
Bai HW; Eom S; Yeom HD; Nguyen KVA; Lee J; Sohn SO; Lee JH
Neuropharmacology; 2019 Mar; 146():65-73. PubMed ID: 30465811
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the phenylalkylamine binding site in hKv1.3 (H399T), a mutant with a reduced C-type inactivated state.
Dreker T; Grissmer S
Mol Pharmacol; 2005 Oct; 68(4):966-73. PubMed ID: 16000530
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory actions of the phosphatidylinositol 3-kinase inhibitor LY294002 on the human Kv1.5 channel.
Wu J; Ding WG; Matsuura H; Tsuji K; Zang WJ; Horie M
Br J Pharmacol; 2009 Jan; 156(2):377-87. PubMed ID: 19154427
[TBL] [Abstract][Full Text] [Related]
15. Charybdotoxin and margatoxin acting on the human voltage-gated potassium channel hKv1.3 and its H399N mutant: an experimental and computational comparison.
Nikouee A; Khabiri M; Grissmer S; Ettrich R
J Phys Chem B; 2012 May; 116(17):5132-40. PubMed ID: 22490327
[TBL] [Abstract][Full Text] [Related]
16. Tst26, a novel peptide blocker of Kv1.2 and Kv1.3 channels from the venom of Tityus stigmurus.
Papp F; Batista CV; Varga Z; Herceg M; Román-González SA; Gaspar R; Possani LD; Panyi G
Toxicon; 2009 Sep; 54(4):379-89. PubMed ID: 19500613
[TBL] [Abstract][Full Text] [Related]
17. Effects of anorexinogen agents on cloned voltage-gated K(+) channel hKv1.5.
Perchenet L; Hilfiger L; Mizrahi J; Clément-Chomienne O
J Pharmacol Exp Ther; 2001 Sep; 298(3):1108-19. PubMed ID: 11504808
[TBL] [Abstract][Full Text] [Related]
18. Open channel block of Kv1.5 channels by HMQ1611.
Dong C; Li J; Ding W; Ueda R; Xie X; Wu J; Matsuura H; Horie M
Front Pharmacol; 2022; 13():965086. PubMed ID: 36188606
[TBL] [Abstract][Full Text] [Related]
19. Cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate and nordihydroguaiaretic acid inhibit human Kv1.5 currents independently of lipoxygenase.
Gong YZ; Ding WG; Wu J; Tsuji K; Horie M; Matsuura H
Eur J Pharmacol; 2008 Dec; 600(1-3):18-25. PubMed ID: 18930721
[TBL] [Abstract][Full Text] [Related]
20. Ginsenoside Rg3 inhibits human Kv1.4 channel currents by interacting with the Lys531 residue.
Lee JH; Lee BH; Choi SH; Yoon IS; Pyo MK; Shin TJ; Choi WS; Lim Y; Rhim H; Won KH; Lim YW; Choe H; Kim DH; Kim YI; Nah SY
Mol Pharmacol; 2008 Mar; 73(3):619-26. PubMed ID: 17959711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
